Prelude Therapeutics Incorporated (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) have recently unveiled a multi-year, multi-program partnership aimed at the exploration, advancement, and market launch of innovative treatments for cancer patients. This collaboration combines Prelude's expertise in targeted protein degradation, medicinal chemistry, and clinical development, combined with AbCellera's proficiency in antibody discovery and development, to create novel precision antibody drug conjugates (ADCs). The inaugural program, benefiting from a selection of antibodies previously discovered by AbCellera, focuses on ADCs that aim to expand the reach of Prelude's small molecule SMARCA2 selective degraders, in order to cater to a larger patient population.

Prelude, commented on the partnership, stating, "By synergizing our collective abilities and proficiency in swiftly discovering and progressing innovative candidates into clinical trials, this collaboration presents an opportunity to construct a pipeline of ADCs that could be groundbreaking, targeting well-established pathways in oncology."

AbCellera, also spoke about the partnership, saying, "Through this strategic alliance, we are uniting our profound knowledge in both antibody and small molecule development to create precision ADC therapies for patients who are in dire need."

In accordance with the terms of the agreement, Prelude and AbCellera will collaborate in the discovery, development, and commercialization of products resulting from this partnership. AbCellera will assume responsibility for manufacturing activities, while Prelude will take the lead in clinical development and global commercialization, though AbCellera retains the option to co-promote any resulting commercial products in the United States.

 

Source: globenewswire.com

Report Abuse